Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer

2.1 Atezolizumab (Tecentriq, Roche) 'in combination with nab‑paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) whose tumours have PD‑L1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease'.

2.2 The dosage schedule is available in the summary of product characteristics.

2.3 The list price for atezolizumab is £2,665.38 per 840 mg/14 ml vial (excluding VAT, BNF online accessed April 2020). The company has a commercial arrangement, which makes atezolizumab available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.